On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
Erfahren Sie mehr 2020-05-18On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien
Erfahren Sie mehr 2020-05-18On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe
Erfahren Sie mehr 2020-04-09On March 17th, the State Council's joint prevention and control mechanism held a press conferenc
Erfahren Sie mehr 2020-03-222020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito
Erfahren Sie mehr 2020-03-01Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide
Erfahren Sie mehr 2020-02-03Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti
Erfahren Sie mehr 2020-01-09Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22
Erfahren Sie mehr 2019-12-21November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical
Erfahren Sie mehr 2019-12-12Flumatinib is a tyrosine kinase inhibitor and it’s a second-generation TK inhibitor drug against Bcr
Erfahren Sie mehr 2019-11-19Recently, Lilly announced that the US FDA approved the company's development of Reyvow (lasmidit
Erfahren Sie mehr 2019-10-20